Baird lowered the firm’s price target on Astrana Health (ASTH) to $50 from $86 and keeps an Outperform rating on the shares. The firm said the long-term story remains attractive but the trajectory feels a litle bit different following its Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health’s Earnings Call: Growth Amid Challenges
- Astrana Health price target lowered to $50 from $86 at Baird
- Astrana Health Reports Strong Revenue Growth in 2024
- Buy Recommendation for Astrana Health: Strong Financial Performance and Strategic Positioning Amid Temporary AI-Related Costs
- Astrana Health Delays Yearly Report Filing